Beta-lactamases Of Gram-negative Bacteria Research Articles

Prevalence of Extended-Spectrum Beta-Lactamase in Gram Negative Bacteria Isolated from Kermanshah Medical Centers: A Systematic Review and Meta-Analysis

Prevalence of Extended-Spectrum Beta-Lactamase in Gram Negative Bacteria Isolated from Kermanshah Medical Centers: A Systematic Review and Meta-Analysis

Structural and Biochemical Evidence That a TEM-1 β-Lactamase N170G Active Site Mutant Acts via Substrate-assisted Catalysis

TEM-1 beta-lactamase is the most common plasmid-encoded beta-lactamase in Gram-negative bacteria and is a model class A enzyme. The active site of class A beta-lactamases share several conserved residues including Ser(70), Glu(166), and Asn(170) that coordinate a hydrolytic water involved in deacylation. Unlike Ser(70) and Glu(166), the functional significance of residue Asn(170) is not well understood even though it forms hydrogen bonds with both Glu(166) and the hydrolytic water. The goal of this study was to examine the importance of Asn(170) for catalysis and substrate specificity of beta-lactam antibiotic hydrolysis. The codon for position 170 was randomized to create a library containing all 20 possible amino acids. The random library was introduced into Escherichia coli, and functional clones were selected on agar plates containing ampicillin. DNA sequencing of the functional clones revealed that only asparagine (wild type) and glycine at this position are consistent with wild-type function. The determination of kinetic parameters for several substrates revealed that the N170G mutant is very efficient at hydrolyzing substrates that contain a primary amine in the antibiotic R-group that would be close to the Asn(170) side chain in the acyl-intermediate. In addition, the x-ray structure of the N170G enzyme indicated that the position of an active site water important for deacylation is altered compared with the wild-type enzyme. Taken together, the results suggest the N170G TEM-1 enzyme hydrolyzes ampicillin efficiently because of substrate-assisted catalysis where the primary amine of the ampicillin R-group positions the hydrolytic water and allows for efficient deacylation.

Roundtable discussion: Cephalosporins in the 1990s and beyond

1'1"'dl'lIl1~ rh... lillm,· " .1h\.IV\ dllli'llit. IIhk...d 1I1'1")\\lhk. Wl' L11I h.I\·... \(lIII~ lh~llnl'\. but 111.111\ .1r~ pl'l)\,t'd wrnll~. PO\\lbh 011,' ,II Ihl' bl·\t \\~\\ (If IO(lklll~ IIl111 Ih~ ,iIlUI" " to \1.11'1 \\ Ilh hl\ton I tiN ht'LlIll" 1Il\', I\'~d \\'lIh lh~ '.:plulo\ponll\ \mlll' Y; Vl"lt'> .I~ I 1111.: \\ mklll~ 111 Edlllhur~h. Sl'olL\IId, III I ')(1-1. I h.1d Ih,' pn\'dq:" <1111,· .In· Ihl' .lIl{1hlllrl':~ Ilflir'l ,hole,' I'!r h"l'l"r1.d 111"III1I~tI\ ,'\','11 1;)1' plI... UIIIl)UlLColl 1ll'·1I11l~1I\. So, lltat: 1\ ~II 01,1 I11dlL1t101l th.lt .11\.11'1'....11''''1 bm h.1\ Cl lilt: hJl'l. ,1~l\1I the u\e of lite Cl'l'Il.llo 1'01111\ 111 I' o!-:ellll lIlelllll~U\ CXf. ) woul.1 Itkt: to dlLcu" th~ cOlltro".. r", b.. l\\'l· ... 1l lit .. lILt: or' ",·plt.llo\ponm or .Jl1Il1lOl-:lyco,,,I,·< III Ih ..· Ir~,ltllll'lll (,I "ck p.ltl~lIt\ \\ IIh UI1"XI'I.III, ...d "'1'\1\. l~'bnk' 11 ... lIlrtll',·llln. l"" (;'·llt.ll1l1'llI b"Col/lle .wJll.lhk· .1t .lpl'r(\XlIll.llCI~ Ihe \,II11t: 1111'<: ,1\ tht: ,·.lrI~ p.1rellta,tl c,·ph.11 "I'0nll\ .1Il.!. t',r IIUII\, y~.'I'\. dlllll'lJI1\ 1<:1t Ih.1I thl' .1I1111Io~lvn"lde\. b...c.lII\l· the' w,''''' I1IOfe hJl'tl·nll'l.1l. \\ ere' h,·It"f drtlf.."; fh.1ll l~pll.llo\p()nm ti.f \lrk p.11I"nt\ wlth 1IIlJI.I!-:r1o\...d \l'I"I\ Howt:"a. t1l1rJ !,l"Il'·r.ltlOIl c... phJJO\ponll\ Jre 1I0W l!\"d /1.11 th .. II1dl(',1t10Ill I'r",vlou\l~ I:.vofl·d 1<11' "'~lIt.1IllI'111 l·\'arlll'll·". 1',·llt.lIlIlCIll 1\ \ull 111 till' ~ul,khllt:\ tor b.lelen.11 "lIdo,·.HdIU\ :111.1 thl" cel'l1.1lo\\,ol1l1\ \tlil h.we not "lUlld .1 ddillll" 1'1:1....: lor th" Illdlc,ulOn Th.. UK r~collllllelld.1I101l\ lor 111t"1 rVI't:\ 01 "mlo ,HdIU\ .If'· til lI\l' .111 .111111101'1 CIl\I.k 1'111' .1 ht:l.l-!.lnJIII. wilich 1\ L1\ll.llly 1I0t ,1 ('t:pll.llo\l'oflll I'mllhl" III th,' futurl' ,Ollle 'thl' Ilewer t·t:pll.ll(1~pnnll\ 1ll,IV 1"1'1.1,,· Ihe .III1'I1(1~I", "O'I,Ie, I~)r th" 111.111,111, 11 J. ACAR

β-Lactamase induction and cell wall recycling in gram-negative bacteria

beta-Lactams with the ability to induce beta-lactamase in gram-negative bacteria bind to essential penicillin-binding proteins (PBPs) after entering the periplasmic space. This leads to inactivation of transpeptidase activities and thereby a decrease in the number of peptide cross-links, allowing further degradation of murein by soluble lytic transglycosylases. If all DD-carboxypeptidases (PBP 4, 5, 6a and 6b) are inhibited as well, the degradation product aD-pentapeptide (N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-glutamyl-meso-diaminopimelic-acid-D-alanyl-D- alanine) accumulates, which is the case with inducing beta-lactams such as imipenem. These molecules in addition to tri- and tetrapeptides (N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-glutamyl-meso-diaminopimelic-acid-[D-alanine]) which are the usual degradation products of peptidoglycan, are released into the cytoplasm and displace the UDP-pentapeptide (UDP-N-acetylmuramyl-L-alanyl-D-glutamyl-meso-diaminopimelic-acid-D-alanyl-D-alanine) from the DNA-binding protein AmpR, converting it into an activator of AmpC beta-lactamase expression.

Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase

Beta-Lactamase is a bacterial protein that provides resistance against beta-lactam antibiotics. TEM-1 beta-lactamase is the most prevalent plasmid-mediated beta-lactamase in gram-negative bacteria. Normally, this enzyme has high levels of hydrolytic activity for penicillins, but mutant beta-lactamases have evolved with activity toward a variety of beta-lactam antibiotics. It has been shown that active site substitutions are responsible for changes in the substrate specificity. Since mutant beta-lactamases pose a serious threat to antimicrobial therapy, the mechanisms by which mutations can alter the substrate specificity of TEM-1 beta-lactamase are of interest. Previously, screens of random libraries encompassing 31 of 55 active site amino acid positions enabled the identification of the residues responsible for maintaining the substrate specificity of TEM-1 beta-lactamase. In addition to substitutions found in clinical isolates, many other specificity-altering mutations were also identified. Interestingly, many nonspecific substitutions in the N-terminal half of the active site omega loop were found to increase ceftazidime hydrolytic activity and decrease ampicillin hydrolytic activity. To complete the active sight study, eight additional random libraries were constructed and screened for specificity-altering mutations. All additional substitutions found to alter the substrate specificity were located in the C-terminal half of the active site loop. These mutants, much like the N-terminal omega loop mutants, appear to be less stable than the wild-type enzyme. Further analysis of a 165-YYG-167 triple mutant, selected for high levels of ceftazidime hydrolytic activity, provides an example of the correlation which exists between enzyme instability and increased ceftazidime hydrolytic activity in the ceftazidime-selected omega loop mutants.

Replacement of serine 237 in class A beta-lactamase of Proteus vulgaris modifies its unique substrate specificity.

The chromosomal beta-lactamase gene of Proteus vulgaris K1 was cloned and sequenced. The gene comprises 813 nucleotides and codes for the mature enzyme of 29,655 Da, comprising 271 amino acids. The K1 beta-lactamase showed 30-70% similarity, in the overall amino acid sequence, to class A beta-lactamases of Gram-negative bacteria. However, the K1 beta-lactamase differs from most class A enzymes in having a unique substrate specificity as a cephalosporinase, its spectrum extending to even oxyiminocephalosporins. To clarify the relationship between its unique substrate specificity and specific amino acid residues, alignment of the amino acid sequence of the K1 beta-lactamase with those of class A beta-lactamases was performed, and Ala104 and Ser237 were found to be candidates. Ala104 and Ser237 were replaced with glutamic acid and alanine, respectively, which are commonly found in other class A beta-lactamases. The substitution at position 104 had no effect on the enzyme activity or the substrate specificity. The amino acid replacement at position 237, however, reduced the kcat/Km value for an oxyiminocephalosporin (cefuroxime) to 17% of that in the case of the wild-type enzyme, whereas the mutant enzyme showed a higher kcat/Km value for benzylpenicillin, 3 times, than that of the wild-type enzyme. These results indicated that Ser237 is one of the residues responsible for the unique substrate specificity of the P. vulgaris beta-lactamase.

Sequences of wild-type and mutant ampD genes of Citrobacter freundii and Enterobacter cloacae.

The ampD gene product regulates the expression of AmpC beta-lactamase in gram-negative bacteria and is proposed to be involved in peptidoglycan metabolism. In this study, we sequenced the ampD wild type and three mutant genes of Enterobacter cloacae and Citrobacter freundii. They exhibited a high degree of homology with the corresponding gene of Escherichia coli except in the carboxy termini, where, in the wild-type genes of E. cloacae and C. freundii, four additional amino acids yielding the Ser-X-X-Lys motif were found. Evidence that this C-terminal region of the ampD gene product is necessary for activity was shown by constructing a deletion of the last 16 amino acids. The spontaneous mutation of ampD02 is an out-of-frame insertion and yields an inactive AmpD protein. The single-base-pair substitution of Gly for Asp-121 in ampD05 is responsible for a hyperinducible phenotype. These results demonstrate regions of the ampD gene and the corresponding protein which have functional importance for the induction of AmpC beta-lactamase in E. cloacae.

Identification of amino acid substitutions that alter the substrate specificity of TEM-1 beta-lactamase.

TEM-1 beta-lactamase is the most prevalent plasmid-mediated beta-lactamase in gram-negative bacteria. Recently, TEM beta-lactamase variants with amino acid substitutions in the active-site pocket of the enzyme have been identified in natural isolates with increased resistance to extended-spectrum cephalosporins. To identify other amino acid substitutions that alter the activity of TEM-1 towards extended-spectrum cephalosporins, we probed regions around the active-site pocket by random-replacement mutagenesis. This mutagenesis technique involves randomizing the DNA sequence of three to six codons in the blaTEM-1 gene to form a library containing all or nearly all of the possible substitutions for the region randomized. In total, 20 different residue positions that had been randomized were screened for amino acid substitutions that increased enzyme activity towards the extended-spectrum cephalosporin cefotaxime. Substitutions at positions 104, 168, and 238 in the TEM-1 beta-lactamase that resulted in increased enzyme activity towards extended-spectrum cephalosporins were found. In addition, small deletions in the loop containing residues 166 to 170 drastically altered the substrate specificity of the enzyme by increasing activity towards extended-spectrum cephalosporins while virtually eliminating activity towards ampicillin.

Induction of beta-lactamase in Gram-negative bacteria

The induction of beta-lactamase in Gram-negative bacteria in vitro has been established. It is possible to distinguish between high and low beta-lactamase inducers in vitro. This differentiation is clinically irrelevant because induction has little effect on the treatment of a bacterial infection with beta-lactam antibiotics. Regardless of the amount of induced beta-lactamase, the kill kinetics are usually not affected. In mutated cells, the regulatory mechanism is destroyed by inactivation of the relevant genes with respect to their regulatory function, particularly by inactivation of the amp D gene. These mutants overproduce the beta-lactamase constitutively, which results in an enzyme level that significantly exceeds the induced level. The induction process is probably not the cause of clinical failures associated with the use of beta-lactam antibiotics. It is concluded that the selection of resistant mutants with constitutive overproduction of beta-lactamase is the reason for most of these treatment failures.

Antibacterial Activity of Tigemonam Dicholate (SQ 30836) and Interaction With Beta-Lactamases of Gram-Negative Bacteria.

SQ 30836 is an orally absorbed salt of tigemonam, a new monobactam similar to aztreonam in structure and microbiologic properties. When assayed against 400 clinical isolates, tigemonam's activity was similar to that of aztreonam and carumonam. It was highly effective against Enterobacteriaceae but showed poor activity against gram-positive organisms. It inhibited 90% of Escherichia coli, Klebsiella, Shigella, Yersinia, Proteus, Providencia, and Morganella strains at 0.5μ/mL or less, and all Salmonella and Hafnia strains at 1 μg/mL or less. Citrobacter, Enterobacter, and Serratia strains were less susceptible (minimum inhibitory concentrations [MIC30] of 2, 32, and 8 μg/mL respectively). The activity of the new compound against Enterobacteriaceae is comparable with and often higher than that of third-generation cephalosporins and oral comparison compounds. In contrast to aztreonam, tigemonam had minimal activity against Pseudomonas sp and glucose nonfermenting gram-negative bacteria. Data suggest that poor penetration through the outer membranes of Pseudomonas sp may be responsible for this failure. Tigemonam was stable to hydrolysis by plasmid-mediated and chromosomal beta-lactamases. It was more stable than aztreonam to hydrolysis by the Kl enzyme of Klebsiella and by the Proteus vulgaris beta-lactamase. Also, measurement of the IC50 (concentration of inhibitor able to reduce the activity of the enzyme by 59%) showed that tigemonam has less affinity than aztreonam for class I cephalosporinases. However, only levels of beta-lactamase, not hydrolysis rates or affinity, correlated to MICs of the two monobactams for the resistant Enterobacter and Citrobacter strains.

Characterization of beta-lactamases in situ on polyacrylamide gels.

An inhibitor-based characterization system which allowed the identification of beta-lactamases after isoelectric focusing on polyacrylamide gels was developed. This system, using potassium clavulanate and oxacillin, distinguished type I chromosomally mediated enzymes from other beta-lactamases of gram-negative bacteria.

The place of temocillin in the treatment of hospital infections.

Infection due to Gram-negative bacteria continues to be a common problem in the hospital environment, for which a wide variety of antibiotics is available. Among Enterobacteria, resistance is expressed most commonly via beta-lactamases. Temocillin is the first penicillin to show stability to beta-lactamases of Gram-negative bacteria, therefore it is in this type of infection that the initial assessments of temocillin should be made.

Differences between Cephalothin and Newer Parenterally Absorbed Cephalosporins in Vitro: A Justification for Separate Disks

The activities of cefamandole and cefoxitin in vitro were compared with that of cephalothin against staphylococci and gram-negative bacilli. Cephalothin was the most active agent against staphylococci. Cefamandole exhibited the greatest activity against the Enterobacteriaceae, with the exceptions of Serratia marcescens and indole-positive Proteeae, against which cefoxitin was the most active antibiotic. The activity of newer cephalosporins that are resistant to the beta-lactamases of gram-negative bacteria renders untenable the status of cephalothin as the class representative of the cephalosporins for susceptibility testing.